-
1st study finds surge of weight loss drugs in health system
A California health system has noted an "exponential" increase in patients using Wegovy, Mounjaro and other similar drugs for weight loss, according to a first-of-its-kind study. -
Drugmaker to lay off 100+ after Biogen acquisition
Reata Pharmaceuticals — a rare disease drugmaker recently acquired by Biogen — filed a WARN notice Oct. 9, alerting Texas officials of its plans to cut 113 positions. The layoffs will take effect Nov. 27. -
Pharmacy group urges US to block Optum-Amedisys deal
Independent pharmacies and lawmakers are asking the federal government to probe UnitedHealth Group's proposed scoop of Amedisys, one of the largest home health and hospice care providers in the U.S. -
Hospitals push back on CMS' drug shortage solution
Hospital groups and healthcare think tanks are urging CMS to revise its proposal to address medication shortages, which have been persistent for decades and have struck multiple therapeutic areas in 2023. -
Pfizer sets list price for Paxlovid
Pfizer has set the list price for a five-day course of Paxlovid at $1,390, according to an exclusive report from The Wall Street Journal. -
OptumRx opens integrated pharmacy in Arizona
UnitedHealth Group's pharmacy care business OptumRx has opened a location in Mesa, Ariz., according to an Oct. 17 news release. -
Amazon begins prescription drone delivery in Texas
Amazon's pharmacy customers in College Station, Texas, can now receive their prescriptions via drone delivery in under an hour, the company announced Oct. 18. -
HHS, Pfizer begin commercialization plans for Paxlovid
Beginning in January, commercialization of Pfizer's Paxlovid antiviral medication will begin and could drive out-of-pocket prices north of $500 before insurance, according to CNN. -
The No. 1 priority among hospital pharmacy leaders
Similar to many healthcare sectors, staffing shortages are compounding issues for hospital pharmacy leaders, according to a LinkedIn poll conducted by Becker's. -
'Weight-loss drug wealth' shows up in charitable giving
Nonprofit foundations aligned with Eli Lilly and Novo Nordisk are now among the largest in the world due to surging sales of drugs like Ozempic, Wegovy and Mounjaro, The Wall Street Journal reports. -
Alzheimer's drug researcher accused of 'egregious misconduct'
Clinical trials for simufilam, an Alzheimer's drug made by Cassava Sciences, will continue even after one of its lead researchers has been accused of "long-standing and egregious misconduct in data management and record keeping," The New York Times reported Oct. 14. -
Cuban's Cost Plus partners with Alto Pharmacy to expand access
San Francisco-based Alto Pharmacy, will now accept Team Cuban Cards from Mark Cuban Cost Plus Drug Co., members, according to an Oct. 16 news release. -
Common antibiotic may be linked to neurological dysfunction, study says
Researchers found very little difference in the outcomes of patients hospitalized with acute kidney injuries who received different antibiotics — cefepime or piperacillin-tazobactam — as treatment, according to the study published Oct. 14 in JAMA. -
Walgreens, CVS workers plan nationwide strike
Pharmacy employees at Walgreens and CVS are in talks to organize nationwide walkouts and protests in late October, people familiar with the matter told CNBC. -
Kaiser pharmacy workers continue 3-week strike, approve to double it
As hundreds of pharmacy workers for Kaiser Permanente continue striking for up to three weeks in Oregon and Southwest Washington, their union approved another strike that could last almost four more weeks. -
Mounjaro helps patients lose 60+ pounds in study
Mounjaro (tirzepatide), Eli Lilly's Type 2 diabetes drug, helped obese and overweight adults lose an average of 64 pounds after 84 weeks in a phase 3 trial. -
The cost of defending a pharmacist license grew 43% in 5 years
Liability claims and incidents involving pharmacists have risen in individual cost, according to a new industry report. -
Paxlovid popularity dwindles
When Pfizer's antiviral Paxlovid entered the U.S. market in December 2021, it quickly became the preferred COVID-19 drug. Nearly two years later, physicians aren't writing many prescriptions for the therapy once touted as a "breakthrough," NBC News reported. -
Texas pharmacy must pay $275K over unlawful opioid distribution
A San Antonio-based pharmacy and pharmacist have been ordered by a federal court to pay $275,000 for the unlawful distribution of opioid and benzodiazepine prescriptions, according to an Oct. 11 news release. -
UVA Health selects chief pharmacy officer
Danielle Griggs, PharmD, will be the chief pharmacy officer of Charlottesville, Va.-based UVA Health, effective Oct. 18.
Page 29 of 50